Key result
Experts favor low-dose aspirin for antiphospholipid syndrome prophylaxis, reserving coumadin or LMWH for high-risk patients.
Answers are grounded in this paper and cite their sources.
Hypothetical circumstances that may require prophylaxis for a potential antiphospholipid syndrome (primary prophylaxis), or in some instances when there already had been some manifestations ofthe syndrome (secondary prophylaxis), were presented to a panel of experts for their consideration on potential prophylactic intervention. These were subsequently presented to the participants in the First International Consensus on Treatment of the Antiphospholipid Syndrome. In most instances there was consensus in adding low dose aspirin, an exception being aspirin allergy when other antiaggregants could be used in nonpregnant subjects. General measures to prevent thrombosis and other vasoprotective actions should also be provided. Higher risk of fetal loss or thrombosis called for anticoagulation with coumadin in nonpregnant subjects or subcutaneous low molecular weight heparin in pregnant ones. When indicated, prophylaxis of the antiphospholipid syndrome should be provided in systemic lupus erythematosus patients who are being treated for their disease. In no instance should corticosteroids or immunosuppresants be given as prophylactic of an antiphospholipid syndrome.
No takes yet. Share an insight, caveat, or question.
Alarcón-Segovia et al. (2003) studied Antiphospholipid syndrome. Low-dose aspirin, coumadin, or subcutaneous low molecular weight heparin was evaluated on Prevention of thrombosis and fetal loss in antiphospholipid syndrome. Low-dose aspirin achieved expert consensus for antiphospholipid syndrome prophylaxis, with coumadin or LMWH reserved for higher risk of thrombosis or fetal loss.
Synapse has enriched 10 related papers. Consider them for comparative context: